Gonadal hormone function and uterine volume after HSCT according to the conditioning regimen
| Sex/age at HSCT . | Parameter . | Outcome . | Busulfan–based conditioning regimen . | TBI–based conditioning regimen . |
|---|---|---|---|---|
| Adult women who underwent transplantation before puberty | Ovarian hormone function28 | Immediate POI∗ (pubertal induction required) | 60% | |
| Spontaneous menarche with secondary POI during the 10 y after puberty | 20% | |||
| Spontaneous menarche without POI at 10 y after puberty | 20% | |||
| Favorable risk factor | Younger age at HSCT | |||
| Uterus volume29 | Uterine volume† (vs general population) | 45% volume reduction | 75% volume reduction | |
| Favorable risk factor | Hormone level‡ and younger age at HSCT | None | ||
| Adult men | Leydig cell function11 | Total testosterone deficiency§ | 25% | 45% |
| Partial testosterone deficiency | 15% | 15% | ||
| No testosterone deficiency | 60% | 35% | ||
| Favorable risk factor | Older at HSCT | |||
| Sex/age at HSCT . | Parameter . | Outcome . | Busulfan–based conditioning regimen . | TBI–based conditioning regimen . |
|---|---|---|---|---|
| Adult women who underwent transplantation before puberty | Ovarian hormone function28 | Immediate POI∗ (pubertal induction required) | 60% | |
| Spontaneous menarche with secondary POI during the 10 y after puberty | 20% | |||
| Spontaneous menarche without POI at 10 y after puberty | 20% | |||
| Favorable risk factor | Younger age at HSCT | |||
| Uterus volume29 | Uterine volume† (vs general population) | 45% volume reduction | 75% volume reduction | |
| Favorable risk factor | Hormone level‡ and younger age at HSCT | None | ||
| Adult men | Leydig cell function11 | Total testosterone deficiency§ | 25% | 45% |
| Partial testosterone deficiency | 15% | 15% | ||
| No testosterone deficiency | 60% | 35% | ||
| Favorable risk factor | Older at HSCT | |||
The data presented are from the LEA program.
Premature ovarian insufficiency (POI) is defined as the association of an oligo/amenorrhea for at least 4 months and an elevated follicle-stimulating hormone (FSH) level >25 IU/L on 2 occasions at 4 weeks apart before age 40 years of age.
Using MRI evaluation.
Either normal ovarian function or hormone replacement therapy.
Total testosterone deficiency was defined as a testosterone level <12 nmol/L or testosterone replacement therapy. Partial testosterone deficiency was defined as normal testosterone levels with elevated luteinizing hormone (LH) levels >10 IU/L. Leydig-cell function was considered normal when testosterone and LH levels were normal without hormone substitution.